Products - B2C

Disclaimer: Availability of products is subject to patent restrictions in countries where applicable patents are in effect.

Download PDF
Product Name Strength and Dosage form Brand/Innovator Indication Dossier Availability
NILOTINIB 50mg, 150mg and 200mg Capsules, hard Tasigna® (Novartis) Lymphoma, Leukemia Q2-2025
FINGOLIMOD* 0.5mg Capsules, hard Gilenya® (Novartis) Multiple sclerosis (MS) YES
TERIFLUNOMIDE* 14mg Film-coated tablets Aubagio® (Sanofi) Multiple sclerosis (MS) YES
ERLOTINIB 25mg, 50mg, 100mg, 150mg Film-coated tablets Tarceva® (Roche) Non-small cell lung cancer YES
GEFITINIB 250mg Film-coated tablets Iressa® (AstraZeneca) Non-small cell lung cancer YES
ABIRATERONE ACETATE 250mg and 500mg Film-coated tablets Zytiga® (Janssen) Prostate cancer YES
APALUTAMIDE 60mg Film-coated tablets Erleada® (Janssen) Prostate cancer Q1-2027
ENZALUTAMIDE 40mg, 80mg Film-coated tablets Xtandi® (Astellas) Prostate cancer Q3-2026
PAZOPANIB (as hydrochloride) 200mg, 400mg Film-coated tablets Votrient® (Novartis) Renal cell cancer YES
BARICITINIB 1mg, 2mg, 4mg Film-coated tablets Olumiant® (Eli Lilly) Rheumatoid arthritis Q4-2026

* Available for distribution only.